ALXO ALXO

ALX Oncology Stock Price

16.07
0.00 (0.0%)
16.07
Volume 0
Bid Price 15.01
Ask Price 22.38
News -
Day High

Low
15.93

52 Week Range

High
89.04

Day Low
Best deals to access real time data!
Big Cap Pro
Monthly Subscription
for only
$52.04
Small Cap Basic
Monthly Subscription
for only
$33.03
Real-Time Alerts for Volume Breakouts, Highs and Lows for NYSE, NASDAQ, Amex, OTC Markets and OTCBB
Monthly Subscription
for only
$67.09
VAT not included
Company Name Stock Ticker Symbol Market Type
ALX Oncology Holdings Inc ALXO NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
0.00 0.0% 16.07 04:00:55
Open Price Low Price High Price Close Price Prev Close
16.07
Last Trade Time Type Quantity Stock Price Currency
- 0 $ 16.07 USD

Period:

Draw Mode:

ALX Oncology Holdings Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 650.83M 40.50M 17.63M $ 1.18M $ - -1.07 -11.50
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - - -436.67k 1.90%

more financials information »

ALX Oncology News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical ALXO Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week18.2018.8215.9317.20615,468-2.13-11.7%
1 Month23.2623.380515.9319.21438,703-7.19-30.91%
3 Months57.3862.3815.9329.64514,462-41.31-71.99%
6 Months57.4181.1915.9343.99370,447-41.34-72.01%
1 Year83.4389.0415.9352.77301,436-67.36-80.74%
3 Years30.44117.4515.9353.91256,951-14.37-47.21%
5 Years30.44117.4515.9353.91256,951-14.37-47.21%

ALX Oncology Description

ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company. The firm is focused on developing therapies that block the CD47 checkpoint pathway and bridge the innate and adaptive immune system. Its lead product candidate under development, ALX148, is a next-generation CD47 blocking therapeutic for the treatment of first-line head and neck cancer and second-line gastric/gastroesophageal junction cancer and breast cancer.


Your Recent History
NASDAQ
ALXO
ALX Oncolo..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.